Medtronic FY2027 Q1 Earnings: $9.76B Revenue, a 53-Week Calendar, and Cardiac Ablation at +88%

Medtronic closed a 14-week first quarter of fiscal 2027 with $9.756 billion of revenue (+13.7% reported and organic), $1.470 billion of GAAP net income, and GAAP diluted EPS of $1.14 — then raised full-year organic growth and non-GAAP EPS guidance. The product story is Cardiac Ablation Solutions at +88%. The calendar story is harder: FY2027 is a 53-week year, and the company puts the extra week in Q1. Readers who want the growth rate that survives the calendar have to hold both numbers at once.

The Headline Numbers​

Medtronic’s fiscal year ends on the last Friday of April. FY2026 closed 2026-04-24. Q1 FY2027 is the 14 weeks ended 2026-07-31 (about 97 calendar days) — not a normalized 13-week slice. GAAP figures below come from the September 1 Exhibit 99.1 and the Form 10-Q for the same period (accession 0001628280-26-060473).

Reported revenue growth and organic growth are the same print: +13.7%, and the release says that landed roughly 200 basis points above the guidance midpoint. GAAP operating margin moved to 18.1% (+120 bp). GAAP net income and diluted EPS rose 41.4% and 40.7%.

Results were impacted by the extra fiscal week, which occurred in Medtronic’s first quarter of FY27. The company estimates the impact of the extra week benefited Q1 organic growth by approximately $570 million.

That sentence is the release’s own estimate, stated here verbatim. $570M is about 5.8% of the $9.756B quarter. Back out the week and the remaining revenue is roughly $9.19B versus prior-year Q1’s $8.578B — closer to +7%, which is the order of magnitude of the raised full-year organic guide (7.25%–7.75%). The ledger does not normalize the week away: the period file is dated through 2026-07-31, and the banner records the 14-week / 53-week fact.

Guidance from the same release: FY27 organic revenue growth raised 50 bp to 7.25%–7.75% (from 6.75%–7.25%), and FY27 diluted non-GAAP EPS raised to $5.94–$6.00. Non-GAAP diluted EPS for the quarter was $1.45, ahead of guidance. This post’s ledger and tables stay on GAAP.

Revenue Deep Dive​

Portfolio revenue from Exhibit 99.1 (reported dollars; organic growth in the release’s language):

Cardiovascular is the growth engine and the thesis carrier. The release: “Cardiovascular grew 18.9%, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions.” Electrophysiology Therapies printed a high-20s increase on the new portfolio taxonomy; Interventional Cardiology Therapies and CardioVascular Surgery were high-single digit; Peripheral Vascular Health low-double digit — all on an organic basis where the release gives that cut. Ablation at +88% is not a rounding error on a $3.9B portfolio: it is the product ramp the rest of the print has to be read against.

Neuroscience grew 9.3% organic. The release ties it to “13% growth in Cranial and Spinal Technologies, including low-20s growth in enabling technology,” with Altaviva “meaningfully contributed to 15% growth in Pelvic Health.” Specialty Therapies high-single digit; Neuromodulation low-single digit — broad, not one-product.

Medical Surgical was “up 10.2%” organic, “led by 9% growth in Surgical and 14% growth in Acute Care & Monitoring.” Surgical & Endoscopy high-single digit; Acute Care & Monitoring mid-teens. This is the steadier hospital-procedure book beside the ablation spike.

Diabetes at $843M (+16.9% reported / +14.9% organic) still sits inside the Medtronic consolidation while the company works through a capital-markets separation. The release warns Diabetes as reported by Medtronic will not match MiniMed carve-out / standalone figures — treat the line as Medtronic’s segment view, not the IPO perimeter.

Management signal scan (Exhibit 99.1, September 1, 2026):

• New product / ramp language: Cardiac Ablation Solutions at +88%; expanded CE Mark for Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmias.
• Broad demand, not “sold out”: “delivers broad-based portfolio performance”; no “demand exceeds supply” or “sold out” wording in this release.
• Guidance as the demand tell: organic revenue guide raised 50 bp and non-GAAP EPS guide raised in the same breath as the Q1 beat.

Tie the ablation claim to the ledger the only way a consolidated P&L allows: total Income:Revenue is 9756 MUSD. Segment dollars live in the release, not as separate Beancount accounts — the chart stays company-wide so Medtronic stays diffable against every other open ledger.

The Margin Story​

Gross margin is flat at 65.0% YoY for the quarter — cost of revenue scaled almost one-for-one with sales (+13.8% vs +13.7%). The operating-margin expansion (+120 bp to 18.1%) is therefore below the gross line: SG&A $3,198M, R&D $771M, and the residual operating items the release folds into the GAAP operating profit bridge (amortization, other operating). Net margin jumped harder (12.1% → 15.1%) with a $289M tax line against $1,769M of pre-tax income in companyfacts — a lighter tax print than the prior-year quarter’s mix, not a gross-margin miracle.

Pricing language in the release is thin. Medtronic is not advertising ASP lifts; it is advertising ablation growth, portfolio breadth, and a raised guide. The margin story that matches the ledger is mix and operating leverage on a flat gross margin, with the extra week inflating the absolute dollars in every line.

The One Big Question: How Much of +13.7% Survives a 52-Week Year?​

Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results.

That is the company’s framing. Three ways to hold it:

The raised FY27 organic guide (7.25%–7.75%) sits next to that third row, not the first. Bulls argue ablation (+88%) and Cardiovascular (+18.9% organic) are real franchise gains that will still print after the calendar normalizes. Bears argue a 14-week quarter plus a diabetes separation mid-story makes run-rate reading noisy until three clean 13-week prints exist. The ledger’s job is narrower: keep the period end at 2026-07-31, keep revenue at 9756 MUSD, and force every reader to see the week in the banner instead of silently annualizing it away.

Inventories are the balance-sheet companion to a device ramp: $6,215M at quarter-end, up from $5,951M at FY2026 year-end and $5,476M a year before that — modeled as Assets:Current:Inventories, not buried in Other.

Tracking a $93B Device Company in Plain Text​

Double-entry does not care whether a quarter has 13 weeks or 14. It only cares that every dollar of assets is claimed by liabilities and equity, and that the income statement zeros. That is how we model every company in this series.

The Q1 income statement in the ledger (Income credits negative, expenses positive; Equity:Adjustments absorbs net income so the transaction sums to zero):

; FY2027Q1 Income Statement (14-week quarter; 53-week FY2027 — extra week not normalized)
; Revenue: 9756 | CoR: 3416 | R&D: 771 | SG&A: 3198 | Tax: 289 | OtherNet: 612 | Net Income: 1470
; Check: −9756 + 3416 + 771 + 3198 + 289 + 612 + 1470 = 0 ✓
 
2026-07-31 * "Medtronic plc" "FY2027Q1 Income Statement"
  Income:Revenue                         -9756 MUSD
  Expenses:CostOfRevenue                   3416 MUSD
  Expenses:ResearchAndDevelopment          771 MUSD
  Expenses:SellingGeneralAdministrative    3198 MUSD
  Expenses:IncomeTax                       289 MUSD
  Expenses:OtherNet                        612 MUSD
  Equity:Adjustments                      1470 MUSD  ; net income offset (RE set by balance assertion)

The balance-sheet number that carries the multi-year arc is goodwill: $41,425M at FY2023 → $43,187M at Q1 FY2027, while finite-lived intangibles run the other way ($14,844M → $10,238M) as amortization eats the acquired book. Inventories rising through the ablation ramp are the working-capital tell beside that M&A residue.

The Multi-Year Arc​

Four annuals show a company that grew revenue from $31.2B to $36.4B while net income recovered from the FY2024 soft patch ($3.68B) to $4.80B. Assets are a slow grind higher around $90–93B; the composition shift is inventories and goodwill up, intangibles down. Q1 FY2027’s absolute dollars are not annualizable without the 53-week caveat — which is why the table keeps the quarter on its own row.

The Verdict: Bull vs. Bear​

Bull Case

• Cardiac Ablation Solutions at +88% with an expanded CE Mark is a durable electrophysiology franchise, not a one-quarter stocking spike.
• Cardiovascular organic +18.9% broadens beyond ablation (CRM +15%, high-single-digit interventional and surgery).
• GAAP operating margin +120 bp to 18.1% with flat gross margin is operating leverage, not price fiction.
• FY27 organic guide raised to 7.25%–7.75% and non-GAAP EPS to $5.94–$6.00 after a beat — management is not walking back the year.
• Inventories building into the ramp ($6.2B) while the ledger still ties at $93.3B of assets.

Bear Case

• The release’s own approximately $570 million extra-week estimate means a large slice of +13.7% is calendar, and the ex-week math (~+7%) is merely in line with the raised guide.
• Diabetes separation timing and perimeter differences versus MiniMed make the 9% segment hard to underwrite from Medtronic’s print alone.
• Gross margin stuck at 65.0% — no pricing momentum language to defend further expansion.
• Goodwill already $43.2B of a $93.3B balance sheet; ablation growth that arrives via M&A rather than organic share gains would thicken that line further.
• One 14-week quarter is a weak base for claiming a multiyear upcycle the release never names.

Our Take. Take the ablation print and the guidance raise seriously; take the $570M week equally seriously. The honest read is a high-teens Cardiovascular franchise printing through a 53-week distortion, not a sudden step-change to mid-teens consolidated growth. The open ledger keeps both facts on one page: revenue 9756 MUSD on 2026-07-31, banner explicit about fourteen weeks, and a zero-sum income statement anyone can re-check.